Top

Published in:

01-04-2020 | NSCLC | Original Article

Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues

Authors: Igor P. Oscorbin, Alexandra S. Shadrina, Vadim V. Kozlov, Vladimir E. Voitsitsky, Maxim L. Filipenko

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

EGFR tyrosine-kinase inhibitors (TKIs) are used as targeted therapeutics for the treatment of advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations. EGFR C797S is common causes of acquired resistance to third-generation TKIs. There is wide-spread opinion that resistance-conferring mutation present even in a small proportion of cancer cells before the start of therapy could potentially predict poor response to a targeted drug. In our study, we tested whether C797S can be found in previously untreated NSCLCs. We analyzed DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 470 lung adenocarcinoma patients, including 235 samples with activating EGFR mutations. Screening was performed using highly sensitive droplet digital PCR assay. No tumor samples with baseline C797S were identified. C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.

Metro G (2018) EGFR targeted therapy for lung cancer: are we almost there? Transl Lung Cancer Res 7:S142–S145. https://doi.org/10.21037/tlcr.2018.03.11 CrossRefPubMedPubMedCentral

Bollinger MK, Agnew AS, Mascara GP (2018) Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract 24:379–388. https://doi.org/10.1177/1078155217712401 CrossRefPubMed

Lu X, Yu L, Zhang Z, Ren X, Smaill JB, Ding K (2018) Targeting EGFR ^L858R/T790M and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: current developments in medicinal chemistry. Med Res Rev 38:1550–1581. https://doi.org/10.1002/med.21488 CrossRefPubMed

Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473–481. https://doi.org/10.1038/nrclinonc.2014.104 CrossRefPubMed

Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators (2018) Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N Engl J Med 378:113–125. https://doi.org/10.1056/NEJMoa1713137 CrossRefPubMed

Walter AO, Sjin RTT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3:1404–1415. https://doi.org/10.1158/2159-8290.CD-13-0314 CrossRefPubMedPubMedCentral

Kim ES (2016) Olmutinib: first global approval. Drugs 76:1153–1157. https://doi.org/10.1007/s40265-016-0606-z CrossRefPubMed

Lelais G, Epple R, Marsilje TH, Long YO, McNeill M, Chen B, Lu W, Anumolu J, Badiger S, Bursulaya B, DiDonato M, Fong R, Juarez J, Li J, Manuia M, Mason DE, Gordon P, Groessl T, Johnson K, Jia Y, Kasibhatla S, Li C, Isbell J, Spraggon G, Bender S, Michellys PY (2016) Discovery of ( R , E )- N -(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H -benzo[ d ]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers. J Med Chem 59:6671–6689. https://doi.org/10.1021/acs.jmedchem.5b01985 CrossRefPubMed

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR (2017) A phase I, dose escalation study of oral ASP8273 in patients with non–small cell lung cancers with epidermal growth factor receptor mutations. Clin Cancer Res 23:7467–7473. https://doi.org/10.1158/1078-0432.CCR-17-1447 CrossRefPubMedPubMedCentral

10.

Xu X (2015) Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Chin J Cancer 34:27. https://doi.org/10.1186/s40880-015-0029-3 CrossRefPubMedCentral

11.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21:560–562. https://doi.org/10.1038/nm.3854 CrossRefPubMedPubMedCentral

12.

Chen L, Fu W, Zheng L, Liu Z, Liang G (2018) Recent Progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. J Med Chem 61:4290–4300. https://doi.org/10.1021/acs.jmedchem.7b01310 CrossRefPubMed

13.

Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N, Date H (2006) Presence of Epidermal Growth Factor Receptor gene T790M mutation as a minor clone in non–small cell lung cancer. Cancer Res 66:7854–7858. https://doi.org/10.1158/0008-5472.CAN-06-1951 CrossRefPubMed

14.

Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25:423–428. https://doi.org/10.1093/annonc/mdt573 CrossRefPubMedPubMedCentral

15.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315–1316. https://doi.org/10.1038/ng1671 CrossRefPubMed

16.

Gazdar A, Robinson L, Oliver D, Xing C, Travis WD, Soh J, Toyooka S, Watumull L, Xie Y, Kernstine K, Schiller JH (2014) Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol 9:456–463. https://doi.org/10.1097/JTO.0000000000000130 CrossRefPubMedPubMedCentral

17.

Oxnard GR, Heng JC, Root EJ, Rainville IR, Sable-Hunt AL, Shane-Carson KP, Carbone DP, Wiesner GL, Garber JE (2015) Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. J Clin Oncol 33:1505. https://doi.org/10.1200/jco.2015.33.15_suppl.1505 CrossRef

18.

Armbruster DA, Pry T (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29(Suppl 1):S49–S52 https://doi.org/citeulike-article-id:3416410. Accessed 29 Aug 2008.

19.

Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang YP, Wang MZ, Liu CY, Ratcliffe M, McCormack R, Reck M (2017) EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study. Lung Cancer 113:37–44. https://doi.org/10.1016/j.lungcan.2017.08.021 CrossRefPubMed

20.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA (2018) Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to Osimertinib. JAMA Oncol 4:1527–1534. https://doi.org/10.1001/jamaoncol.2018.2969 CrossRefPubMed

21.

Nagano T, Tachihara M, Nishimura Y (2018) Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells 7:212. https://doi.org/10.3390/cells7110212 CrossRefPubMedCentral

22.

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C (2018) Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor Osimertinib in non-small cell lung cancer patients. Clin Cancer Res 24:3097–3107. https://doi.org/10.1158/1078-0432.CCR-17-2310 CrossRefPubMed

23.

Ho C-C, Liao W-Y, Lin C-A, Shih JY, Yu CJ, Chih-Hsin Yang J (2017) Acquired BRAF V600E mutation as resistant mechanism after treatment with Osimertinib. J Thorac Oncol 12:567–572. https://doi.org/10.1016/j.jtho.2016.11.2231 CrossRefPubMed

24.

S-HI O, Cui J, Schrock AB et al (2017) Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 108:228–231. https://doi.org/10.1016/j.lungcan.2017.04.003 CrossRef

25.

Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrão MV, Reis LFL, Katz A, Camargo AA (2017) Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer 108:238–241. https://doi.org/10.1016/j.lungcan.2017.04.004 CrossRefPubMed

26.

van Noesel J, van der Ven WH, van Os TAM, Kunst PWA, Weegenaar J, Reinten RJA, Kancha RK, Duyster J, van Noesel CJM (2013) Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 31:e161–e164. https://doi.org/10.1200/JCO.2012.42.1586 CrossRefPubMed

27.

Ruan Z, Kannan N (2015) Mechanistic insights into R776H mediated activation of epidermal growth factor receptor kinase. Biochemistry 54:4216–4225. https://doi.org/10.1021/acs.biochem.5b00444 CrossRefPubMed

Title: Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues
Authors: Igor P. Oscorbin
Alexandra S. Shadrina
Vadim V. Kozlov
Vladimir E. Voitsitsky
Maxim L. Filipenko
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: NSCLC
Tyrosine Kinase Inhibitors
NSCLC
Tyrosine Kinase Inhibitors
Osimertinib
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00683-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis

Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations

Comparison of CDH1 Gene Hypermethylation Status in Blood and Serum among Gastric Cancer Patients

Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer

The Development and Application of Virtual Reality Animation Simulation Technology: Take Gastroscopy Simulation System as an Example

Keynote webinar | Spotlight on antibody–drug conjugates in cancer